Miami Cancer Institute Precision Oncology Symposium Evaluation - Day 2

Please select one: *

I am in active clinical practice

I am retired

I am a student

Other

Please score your agreement with or assessment of the following questions and statements by rating on a scale of 1 to 5, with 5 representing the highest level of satisfaction or agreement. *

Scoring Key: 5=Strongly Agree 4= Somewhat agree 3=Neither agree nor disagree 2= Somewhat disagree 1=Strongly disagree NA=Not applicable

	5	4	3	2	1	NA
The skills learned in this CME course enhanced my professional competence.	The skills learned in this CME course enhanced my professional competence. - 5	The skills learned in this CME course enhanced my professional competence. - 4	The skills learned in this CME course enhanced my professional competence. - 3	The skills learned in this CME course enhanced my professional competence. - 2	The skills learned in this CME course enhanced my professional competence. - 1	The skills learned in this CME course enhanced my professional competence. - NA
The skills learned in this CME course will be applied in the treatment of my patients.	The skills learned in this CME course will be applied in the treatment of my patients. - 5	The skills learned in this CME course will be applied in the treatment of my patients. - 4	The skills learned in this CME course will be applied in the treatment of my patients. - 3	The skills learned in this CME course will be applied in the treatment of my patients. - 2	The skills learned in this CME course will be applied in the treatment of my patients. - 1	The skills learned in this CME course will be applied in the treatment of my patients. - NA

How confident are you in your ability to: *

5 = High level of confidence 4 = Moderately high level of confidence 3 = Average level of confidence 2 = Low level of confidence 1 = No level of confidence NA|Not applicable to my practice

	5	4	3	2	1
Properly diagnose and manage solid tumor malignancies.	Properly diagnose and manage solid tumor malignancies. - 5	Properly diagnose and manage solid tumor malignancies. - 4	Properly diagnose and manage solid tumor malignancies. - 3	Properly diagnose and manage solid tumor malignancies. - 2	Properly diagnose and manage solid tumor malignancies. - 1
Provide an update of new molecular and targeted treatments being developed for solid tumors..	Provide an update of new molecular and targeted treatments being developed for solid tumors.. - 5	Provide an update of new molecular and targeted treatments being developed for solid tumors.. - 4	Provide an update of new molecular and targeted treatments being developed for solid tumors.. - 3	Provide an update of new molecular and targeted treatments being developed for solid tumors.. - 2	Provide an update of new molecular and targeted treatments being developed for solid tumors.. - 1

How satisfied or dissatisfied were you with the Speaker's effectiveness in addressing the learning objectives? *

Scoring Key: 5=Strongly satisfied 4= Somewhat satisfied 3=Neither satisfied nor dissatisfied 2= Somewhat dissatisfied 1=Strongly dissatisfied

	5	4	3	2	1
Updates in Triple Negative Breast Cancer - Priyanka Sharma, M.D.	Updates in Triple Negative Breast Cancer - Priyanka Sharma, M.D. - 5	Updates in Triple Negative Breast Cancer - Priyanka Sharma, M.D. - 4	Updates in Triple Negative Breast Cancer - Priyanka Sharma, M.D. - 3	Updates in Triple Negative Breast Cancer - Priyanka Sharma, M.D. - 2	Updates in Triple Negative Breast Cancer - Priyanka Sharma, M.D. - 1
HER2+ Breast Cancer: Treatment for the Continuum of HER2 Expression - Kelly Mccann, M.D., Ph.D	HER2+ Breast Cancer: Treatment for the Continuum of HER2 Expression - Kelly Mccann, M.D., Ph.D - 5	HER2+ Breast Cancer: Treatment for the Continuum of HER2 Expression - Kelly Mccann, M.D., Ph.D - 4	HER2+ Breast Cancer: Treatment for the Continuum of HER2 Expression - Kelly Mccann, M.D., Ph.D - 3	HER2+ Breast Cancer: Treatment for the Continuum of HER2 Expression - Kelly Mccann, M.D., Ph.D - 2	HER2+ Breast Cancer: Treatment for the Continuum of HER2 Expression - Kelly Mccann, M.D., Ph.D - 1
Targeted Therapy for ER+/HER2 negative Metastatic Breast Cancer: CDK4/6i and Beyond - Seth Wander, M.D., Ph.D.	Targeted Therapy for ER+/HER2 negative Metastatic Breast Cancer: CDK4/6i and Beyond - Seth Wander, M.D., Ph.D. - 5	Targeted Therapy for ER+/HER2 negative Metastatic Breast Cancer: CDK4/6i and Beyond - Seth Wander, M.D., Ph.D. - 4	Targeted Therapy for ER+/HER2 negative Metastatic Breast Cancer: CDK4/6i and Beyond - Seth Wander, M.D., Ph.D. - 3	Targeted Therapy for ER+/HER2 negative Metastatic Breast Cancer: CDK4/6i and Beyond - Seth Wander, M.D., Ph.D. - 2	Targeted Therapy for ER+/HER2 negative Metastatic Breast Cancer: CDK4/6i and Beyond - Seth Wander, M.D., Ph.D. - 1
Dividing and Conquering Sarcomas - Neeta Somaiah, M.D.	Dividing and Conquering Sarcomas - Neeta Somaiah, M.D. - 5	Dividing and Conquering Sarcomas - Neeta Somaiah, M.D. - 4	Dividing and Conquering Sarcomas - Neeta Somaiah, M.D. - 3	Dividing and Conquering Sarcomas - Neeta Somaiah, M.D. - 2	Dividing and Conquering Sarcomas - Neeta Somaiah, M.D. - 1
Evolving Paradigm in Urothelial Cancer - Shilpa Gupta, M.D.	Evolving Paradigm in Urothelial Cancer - Shilpa Gupta, M.D. - 5	Evolving Paradigm in Urothelial Cancer - Shilpa Gupta, M.D. - 4	Evolving Paradigm in Urothelial Cancer - Shilpa Gupta, M.D. - 3	Evolving Paradigm in Urothelial Cancer - Shilpa Gupta, M.D. - 2	Evolving Paradigm in Urothelial Cancer - Shilpa Gupta, M.D. - 1
Urothelial Cancer - Petro Grivas, M.D., Ph.D.	Urothelial Cancer - Petro Grivas, M.D., Ph.D. - 5	Urothelial Cancer - Petro Grivas, M.D., Ph.D. - 4	Urothelial Cancer - Petro Grivas, M.D., Ph.D. - 3	Urothelial Cancer - Petro Grivas, M.D., Ph.D. - 2	Urothelial Cancer - Petro Grivas, M.D., Ph.D. - 1
Precision Oncology in Prostate Cancer - Rohan Garje, M.D.	Precision Oncology in Prostate Cancer - Rohan Garje, M.D. - 5	Precision Oncology in Prostate Cancer - Rohan Garje, M.D. - 4	Precision Oncology in Prostate Cancer - Rohan Garje, M.D. - 3	Precision Oncology in Prostate Cancer - Rohan Garje, M.D. - 2	Precision Oncology in Prostate Cancer - Rohan Garje, M.D. - 1

Was this course fair, balanced and without commercial bias? *

Yes

No

If you checked "No,” please explain why: *

As a result of my participation in this Symposium, I commit to make the following changes to my clinical practice: *

I will discuss the rationale for new targeted diagnostics and therapeutic strategies for lung cancer, breast cancer, gastrointestinal tumors, genitourinary tumors, head and neck tumors, melanoma, sarcoma and brain tumors.

I will review the role and timing of diagnostic tests, immunoblative therapy and re-imaging the evolution with precision oncology paradigm of targeted therapy treatment options.

I will implement the approach of precision oncology in high-grade and low grade gliomas.

I will implement the role of biomarkers in ovarian and cervical cancers.

Not applicable to my practice.

I am retired.

I have not implemented any strategies.

How many patients will you see in your practice who will likely be impacted by what you learned at this activity? *

What, if any, new skills/strategies will you apply in your clinical practice? *

If you do not plan to implement any new skills/strategies in your clinical practice, what is keeping you from doing so? *

Please provide any additional comments or suggestions.

Name

You are here

Miami Cancer Institute Precision Oncology Symposium Evaluation - Day 2